Evidence map›Paper›PMID 34795636›Full record

ArticleFrontiers in endocrinology2021

Myokines in Acromegaly: An Altered Irisin Profile.

Łukasz Mizera, Jowita Halupczok-Żyła, Katarzyna Kolačkov, Agnieszka Zembska, Jędrzej Grzegrzółka, Diana Jędrzejuk, Marek Bolanowski, Jacek Daroszewski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Łukasz MizeraDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Jowita Halupczok-ŻyłaDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Katarzyna KolačkovDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Agnieszka ZembskaDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Jędrzej GrzegrzółkaDepartment of Histology and Embryology, Wrocław Medical University, Wrocław, Poland.
Diana JędrzejukDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Marek BolanowskiDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Jacek DaroszewskiDepartment of Endocrinology, Diabetes and Isotope Therapy, Wrocław Medical University, Wrocław, Poland.
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The muscle is an endocrine organ controlling metabolic homeostasis. Irisin and myostatin are key myokines mediating this process. Acromegaly is a chronic disease with a wide spectrum of complications, including metabolic disturbances. Purpose: To examine the influence of acromegaly on irisin and myostatin secretion and their contribution to metabolic profile and body composition. Materials and Methods: In 43 patients with acromegaly and 60 controls, serum levels of irisin, myostatin, growth hormone (GH), insulin-like growth factor 1 (IGF-1), parameters of glucose, and lipid metabolism were determined. Body composition was assessed with dual-energy x-ray absorptiometry. Results: The irisin concentration was significantly lower in patients with acromegaly compared to controls (3.91 Conclusions: Decreased irisin concentrations in acromegaly may suggest impaired hormonal muscle function contributing to metabolic complications in this disorder. However, learning more about the association between myostatin and GH in acromegaly requires further studies. Nevertheless, it appears that myostatin is not critical for muscle mass regulation in acromegaly.

Indexed as

AcromegalyBiomarkersBody CompositionBody Mass IndexCase-Control StudiesCross-Sectional StudiesFemaleFibronectinsFollow-Up StudiesHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedMusclesMyostatinBiomarkersFibronectinsFNDC5 protein, humanHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor IMSTN protein, humanMyostatinacromegalyGHIGF-1irisinmusclesmyokinesmyostatin

Identifiers

PMID34795636
PMCPMC8593228
OpenAlexW3209422391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.